Abbott India Analysis, Thesis of Business Systems

Download Abbott India Analysis and more Thesis Business Systems in PDF only on Docsity! Abbott India Limited General Overview: Since 1910, Abbott has been dedicated to helping people in India live healthier lives through a diverse range of science-based nutritional products, diagnostic tools, branded generic pharmaceuticals, and diabetes and vascular devices. Headquartered in Mumbai, Abbott India Limited, a publicly listed company and a subsidiary of Abbott Laboratories, takes pride in offering high-quality trusted medicines in multiple therapeutic categories such as women's health, gastroenterology, cardiology, metabolic disorders and primary care. One of India's fastest-growing pharmaceutical companies, Abbott India Limited is part of Abbott's global pharmaceutical business in India. Shareholding Pattern : Holder's Name No of Shares % Share Holding NoOfShares 21249302 100% Promoters 0 0% ForeignInstitutions 43299 0.2% NBanksMutualFunds 1028506 4.84% Others 455702 2.14% GeneralPublic 3127610 14.72% FinancialInstitutions 660137 3.11% ForeignPromoter 15934048 74.99% Management: Vivek V Kamath – Managing Director Mr. Vivek V Kamath has over 30 years of rich and diversified experience in healthcare, including pharmaceuticals, OTC and diagnostics. He has held several senior leadership positions in various reputed pharmaceutical companies, Indian as well as MNCs, across different geographies and holds strong functional expertise in the areas of strategy, marketing, sales & general management. Rajiv Sonalker – CFO and Whole-time Director. Rajiv joined as Director - Finance in November 2006 and has 29 years of experience in the Pharmaceutical, FMCG and Engineering sectors.  Prior to joining Abbott India, he worked with Bristol-Myers Squibb as Director – Finance.  Rajiv has also worked with Voltas Ltd, Johnson & Johnson, Sanofi - Aventis in India and Germany. Strengths:  Company with high TTM EPS Growth 413.9% returns for Nifty 500 over 5.4 years  Increasing Revenue every Quarter for the past 8 Quarters 77.1% returns for Nifty 500 over 4.5 years  Effectively using its capital to generate profit - RoCE improving in last 2 years -16.8% returns for Nifty 500 over 1.9 years  Effectively using Shareholders fund - Return on equity (ROE) improving since last 2 year  Efficient in managing Assets to generate Profits - ROA improving since last 2 year  Growth in Net Profit with increasing Profit Margin (QoQ)  Growth in Quarterly Net Profit with increasing Profit Margin (YoY)  Company with No Debt  Increasing Revenue every Quarter for the past 4 Quarters  Strong cash generating ability from core business - Improving Cash Flow from operation for last 2 years  Annual Net Profits improving for last 2 years  Book Value per share Improving for last 2 years  Company with Zero Promoter Pledge  Near 52 Week High